Learn more about our industry, technologies, company and capabilities
WuXi Biologics Achieve Record High 2020 Results Despite Challenging Yea
r
Remote Pre-Approval Inspection Completed by EMA on WuXi Biologics’ MFG4 Facility
Read More
WuXi Biologics Receives GMP Certification from Brazil’s ANVISA
Read Mor
e
WuXi Biologics to Acquire CMAB and Form Strategic Partnership with CBC Group
Read More
WuXi Biologics to Acquire Biologics DS and DP Manufacturing Facilities from Pfizer China
Read More
WuXi Biologics to Acquire Drug Substance Facility in Wuppertal, Germany from Bayer
Read More
WuXi Vaccines Achieves Weather-Tight Construction Milestone Despite COVID-19
Read More
The World's Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics
Read More
GMP Inspection Completed by ANVISA at WuXi Biologics DS facility
Read More
WuXi Vaccines Achieves Weather-Tight Construction Milestone Despite COVID-19
Read More
WuXi Biologics standardizes a remarkable 12 month “DNA to IND” timeline through its streamlined development platform
Read More
Our Regulatory Affairs team provides a quarterly summary of updates organized by agency and by topic. These updates support your efforts to stay current in our ever-changing regulatory environment.
For more information - See this Podcast
The Challenge of Staying Current with Regulatory Changes – How one company is providing a solution
Antibody Drug Conjugates (ADC) Drug Development and Manufacturing Trends, Challenges and Solutions
(Webinar)
_______________________________
Expediting Biologics Drug Development: Strategies to Accelerate Preclinical Development Timelines
(Webinar)
_______________________________
Applications and Impact of CRISPR/Cas9 in Bioprocessing
(Podcast)
_____________________________
Continuous Biomanufacturing Implementation – Using an Intensified and Integrated Bioprocess Platform
(White Paper)
_______________________________
The Watershed Moment for ADCs has Arrived
(White Paper)
_______________________________
Reducing Fill Risk in Drug Product Manufacture Utilizing New State-of-the-Art Systems and Platforms
(Podcast)
_______________________________
New Flexible Bispecific Antibody Format Demonstrates Improved Therapeutic Properties And Manufacturability
(White Paper)
_______________________________
Scale-Out Biomanufacturing – A Paradigm Change to Scale-Up
(White Paper)
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline
Read More
WuXi Biologics Congratulates Vir Biotechnology on Positive Data from Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection
Read More
WuXi Biologics, WuXi STA and Antengene Announce Collaboration to Advance Antibody-Drug Conjugate Candidate into Clinical Stage
Read More
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform
Read More
Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation
Read More
WuXi Biologics Wins 2021 CMO Leadership Awards in All Six Core Categories
To read more about WuXi Biologics visit our
Newsletter Archive
